Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers

Completed · Phase 2 · Has a placebo group

Conditions studied: Lung Carcinoma, Tobacco Use Disorder

In brief

This randomized phase II trial studies the safety and effects of acetylsalicylic acid (aspirin) taken continuously or intermittently on gene expression in the nasal tissue of current smokers. Smokers are at increased risk of developing lung cancer. Acetylsalicylic acid may be useful in preventing lung cancer.

Key facts

Study ID
NCT02123849
Run by
National Cancer Institute (NCI)
People needed
54
Starts
2014-06-01
Expected to finish
2018-02-01
Last updated by the study team
2018-08-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.